• Similar articles
    Trending: Pivotal
    BostonheraldBostonherald
    Biogen receives FDA approval for breakthrough ALS treatment: ‘Pivotal moment in ALS research’
    Apr 25 2023. Health: Cambridge-based Biogen has gotten the green light for a breakthrough ALS treatment that targets a devastating, ultra-rare genetic form of the progressive neurodegenerative disease. The U.S. Food and…
    Cambridge-based Biogen has gotten the green light for a breakthrough ALS treatment that targets a devastating, ultra-rare genetic form of the progressive neurodegenerative disease. The U.S. Food and…
    Bostonherald
    ReutersReuters
    Biogen publishes Alzheimer's drug data in lesser-known journal
    Mar 17 2022. Health: Biogen publishes Alzheimer's drug data in lesser-known journal Biogen Inc on Wednesday published long-awaited… ...pivotal...
    Biogen publishes Alzheimer's drug data in lesser-known journal Biogen Inc on Wednesday published long-awaited… ...pivotal...
    Reuters
    Similar
    It slowed cognitive decline by 27 per cent after 18 months when compared to a placebo, according to its manufacturers, Tokyo-based Eisai and US firm Biogen
    Sep 28 2022. Health: He said: “The results from Eisai and Biogen for lecanemab are truly encouraging and look like the first truly positive mechanistic trial results in Alzheimer’s disease. The results look modest but real.… ...pivotal...
    He said: “The results from Eisai and Biogen for lecanemab are truly encouraging and look like the first truly positive mechanistic trial results in Alzheimer’s disease. The results look modest but real.… ...pivotal...
    Express
    Similar

    About NewsOwner

    We are tracking and analysing news

    Add website

    Send us news sources you want us to cover

    Advertise

    Advertising and sponsored content

    Contact us

    Send us your comments or questions here

    Copyrights © 2016 - Scanmine Inc. / NewsOwner.com. This publication is automatically generated based on content updated from thousands of sources. All article content are © copyright of their respective owners. Third party content is collected from open sources only and selected, filtered and used by the creator of this publication similar to how third party content is posted by users in social media platforms or generated from search engines and in line with the U.S. "Fair Use Act" and similar laws in other countries allowing limited use of copyrighted material.